{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:26:26Z","timestamp":1778757986808,"version":"3.51.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["SLS-998225 and SLS-1016499"],"award-info":[{"award-number":["SLS-998225 and SLS-1016499"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003748","name":"Swedish Society for Medical Research","doi-asserted-by":"crossref","award":["PG-24-0320"],"award-info":[{"award-number":["PG-24-0320"]}],"id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH Center on Compulsive Behavior"},{"name":"National Institutes of Health Intramural Research Program"},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA029831"],"award-info":[{"award-number":["AA029831"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG057557, AG061388, AG062272, AG076649"],"award-info":[{"award-number":["AG057557, AG061388, AG062272, AG076649"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TR004528"],"award-info":[{"award-number":["TR004528"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Alcohol use disorder (AUD) is a major contributor to the global burden of disease, yet treatments are limited. Therefore, developing evidence-based pharmacotherapies for AUD is critical. Preclinical and clinical studies suggest that spironolactone reduces alcohol intake and could be repurposed for AUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine associations of spironolactone prescription with AUD remission and alcohol intoxication in a real-world population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Target trial emulations were conducted using a population-based analytics platform of electronic health records from over 100 million US patients (TriNetX). Patients with AUD and comorbid hypertension, without prior documented AUD remission, who were prescribed spironolactone were compared with propensity-score matched controls prescribed other antihypertensive medications. The studied outcomes were AUD remission and alcohol intoxication, identified by International Classification of Diseases codes during a one-year follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Spironolactone prescription was associated with a significantly higher hazard rate for AUD remission compared with prescriptions for all other groups of antihypertensive medications, with hazard ratios ranging from 1.24 [95% confidence interval (CI): 1.06\u20131.45] compared to loop diuretics and 2.07 [95% CI: 1.73\u20132.48] compared to angiotensin II receptor blockers. Furthermore, spironolactone prescriptions were associated with a significantly lower hazard rate for alcohol intoxication compared with most other groups of antihypertension medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients prescribed spironolactone were more likely to experience AUD remission and less likely to experience alcohol intoxication compared with propensity score-matched controls. These real-world findings further support the potential of spironolactone as a new pharmacotherapy for AUD and underscore the need for further testing in randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00213-026-07087-8","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:55:13Z","timestamp":1778756113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spironolactone and clinical outcomes in patients with alcohol use disorder and comorbid hypertension: a target trial emulation study"],"prefix":"10.1007","author":[{"given":"Anna","family":"Loften","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"QuanQiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Farokhnia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Kaelber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora D.","family":"Volkow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leandro F.","family":"Vendruscolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"6","key":"7087_CR1","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/mp.2017.97","volume":"23","author":"EG Aoun","year":"2018","unstructured":"Aoun EG, Jimenez VA, Vendruscolo LF, Walter NAR, Barbier E, Ferrulli A, Haass-Koffler CL, Darakjian P, Lee MR, Addolorato G, Heilig M, Hitzemann R, Koob GF, Grant KA, Leggio L (2018) A relationship between the aldosterone-mineralocorticoid receptor pathway and alcohol drinking: preliminary translational findings across rats, monkeys and humans. Mol Psychiatry 23(6):1466\u20131473. https:\/\/doi.org\/10.1038\/mp.2017.97","journal-title":"Mol Psychiatry"},{"key":"7087_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-087179","volume":"390","author":"AG Cashin","year":"2025","unstructured":"Cashin AG, Hansford HJ, Hern\u00e1n MA, Swanson SA, Lee H, Jones MD, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X, Golub RM, Islam N, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sharp MK, Sterne JAC, Stuart EA, McAuley JH (2025) Transparent reporting of observational studies emulating a target trial: the TARGET Statement. BMJ 390:e087179. https:\/\/doi.org\/10.1136\/bmj-2025-087179","journal-title":"BMJ"},{"issue":"6","key":"7087_CR3","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.bja.2025.02.032","volume":"134","author":"S Coppola","year":"2025","unstructured":"Coppola S, Chiumello D, Adnan A, Pozzi T, Forni LG, Gattinoni L (2025) Diuretics in critically ill patients: a narrative review of their mechanisms and applications. Br J Anaesth 134(6):1638\u20131647. https:\/\/doi.org\/10.1016\/j.bja.2025.02.032","journal-title":"Br J Anaesth"},{"key":"7087_CR4","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0835","author":"P Danpanichkul","year":"2025","unstructured":"Danpanichkul P, D\u00edaz LA, Suparan K, Tothanarungroj P, Sirimangklanurak S, Auttapracha T, Blaney HL, Sukphutanan B, Pang Y, Kongarin S, Idalsoaga F, Fuentes-L\u00f3pez E, Leggio L, Noureddin M, White TM, Louvet A, Mathurin P, Loomba R, Kamath PS, Rehm J, Lazarus JV, Wijarnpreecha K, Arab JP (2025) Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021. Clin Mol Hepatol. https:\/\/doi.org\/10.3350\/cmh.2024.0835","journal-title":"Clin Mol Hepatol"},{"key":"7087_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.physbeh.2016.12.045","volume":"178","author":"ER de Kloet","year":"2017","unstructured":"de Kloet ER, Jo\u00ebls M (2017) Brain mineralocorticoid receptor function in control of salt balance and stress-adaptation. Physiol Behav 178:13\u201320. https:\/\/doi.org\/10.1016\/j.physbeh.2016.12.045","journal-title":"Physiol Behav"},{"key":"7087_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109545","volume":"234","author":"ST De Oliveira","year":"2023","unstructured":"De Oliveira ST, Wean S, Katner SN, Hopf FW (2023) The role of beta- and alpha-adrenergic receptors on alcohol drinking. Neuropharmacology 234:109545. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109545","journal-title":"Neuropharmacology"},{"issue":"13","key":"7087_CR7","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1038\/npp.2011.152","volume":"36","author":"R Dorey","year":"2011","unstructured":"Dorey R, Pi\u00e9rard C, Shinkaruk S, Tronche C, Chauveau F, Baudonnat M, B\u00e9racoch\u00e9a D (2011) Membrane mineralocorticoid but not glucocorticoid receptors of the dorsal hippocampus mediate the rapid effects of corticosterone on memory retrieval. Neuropsychopharmacology 36(13):2639\u20132649. https:\/\/doi.org\/10.1038\/npp.2011.152","journal-title":"Neuropsychopharmacology"},{"key":"7087_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26020540","author":"N Ekman","year":"2025","unstructured":"Ekman N, Grossman AB, Nieckarz A, J\u0119drzejewski \u0141, Wolf J, Dworakowska D (2025) Non-hypertensive effects of aldosterone. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26020540","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7087_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/09595230220119282a","volume":"21","author":"M Elisaf","year":"2002","unstructured":"Elisaf M, Liberopoulos E, Bairaktari E, Siamopoulos K (2002) Hypokalaemia in alcoholic patients. Drug Alcohol Rev 21(1):73\u201376. https:\/\/doi.org\/10.1080\/09595230220119282a","journal-title":"Drug Alcohol Rev"},{"key":"7087_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.08.023","volume":"156","author":"A Erol","year":"2015","unstructured":"Erol A, Karpyak VM (2015) Sex and gender-related differences in alcohol use and its consequences: contemporary knowledge and future research considerations. Drug Alcohol Depend 156:1\u201313. https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.08.023","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"7087_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/jan.0000000000000384","volume":"32","author":"LA Farinelli","year":"2021","unstructured":"Farinelli LA, Piacentino D, Browning BD, Brewer BB, Leggio L (2021) Cardiovascular consequences of excessive alcohol drinking via electrocardiogram: a systematic review. J Addict Nurs 32(1):39\u201345. https:\/\/doi.org\/10.1097\/jan.0000000000000384","journal-title":"J Addict Nurs"},{"issue":"8","key":"7087_CR12","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1111\/acer.70099","volume":"49","author":"LA Farinelli","year":"2025","unstructured":"Farinelli LA, Sherman G, Piacentino D, Schwandt ML, Abreu VE, Cooper D, Leggio L (2025) Early signs of cardiovascular abnormalities in patients with alcohol misuse. Alcohol Clin Exp Res 49(8):1704\u20131715. https:\/\/doi.org\/10.1111\/acer.70099","journal-title":"Alcohol Clin Exp Res"},{"issue":"11","key":"7087_CR13","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1038\/s41380-022-01736-y","volume":"27","author":"M Farokhnia","year":"2022","unstructured":"Farokhnia M, Rentsch CT, Chuong V, McGinn MA, Elvig SK, Douglass EA, Gonzalez LA, Sanfilippo JE, Marchette RCN, Tunstall BJ, Fiellin DA, Koob GF, Justice AC, Leggio L, Vendruscolo LF (2022) Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies. Mol Psychiatry 27(11):4642\u20134652. https:\/\/doi.org\/10.1038\/s41380-022-01736-y","journal-title":"Mol Psychiatry"},{"key":"7087_CR14","unstructured":"FDA. (2024). Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products Guidance for Industry DRAFT GUIDENCE. Retrieved March 16th 2026 from https:\/\/www.fda.gov\/media\/177128\/download"},{"issue":"2","key":"7087_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1530-0277.2011.01628.x","volume":"36","author":"HC Fox","year":"2012","unstructured":"Fox HC, Anderson GM, Tuit K, Hansen J, Kimmerling A, Siedlarz KM, Morgan PT, Sinha R (2012) Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. Alcohol Clin Exp Res 36(2):351\u2013360. https:\/\/doi.org\/10.1111\/j.1530-0277.2011.01628.x","journal-title":"Alcohol Clin Exp Res"},{"issue":"8","key":"7087_CR16","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1111\/acer.12789","volume":"39","author":"JC Froehlich","year":"2015","unstructured":"Froehlich JC, Hausauer B, Fischer S, Wise B, Rasmussen DD (2015) Prazosin reduces alcohol intake in an animal model of alcohol relapse. Alcohol Clin Exp Res 39(8):1538\u20131546. https:\/\/doi.org\/10.1111\/acer.12789","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"7087_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00213-010-1967-8","volume":"212","author":"NW Gilpin","year":"2010","unstructured":"Gilpin NW, Koob GF (2010) Effects of \u03b2-adrenoceptor antagonists on alcohol drinking by alcohol-dependent rats. Psychopharmacology Berl 212(3):431\u2013439. https:\/\/doi.org\/10.1007\/s00213-010-1967-8","journal-title":"Psychopharmacology Berl"},{"issue":"9","key":"7087_CR18","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1001\/jamapsychiatry.2017.2161","volume":"74","author":"BF Grant","year":"2017","unstructured":"Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, Huang B, Jung J, Zhang H, Fan A, Hasin DS (2017) Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001\u20132002 to 2012\u20132013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiat 74(9):911\u2013923. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.2161","journal-title":"JAMA Psychiat"},{"issue":"10","key":"7087_CR19","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1111\/acer.13859","volume":"42","author":"RA Grucza","year":"2018","unstructured":"Grucza RA, Sher KJ, Kerr WC, Krauss MJ, Lui CK, McDowell YE, Hartz S, Virdi G, Bierut LJ (2018) Trends in adult alcohol use and binge drinking in the early 21st-century United States: a meta-analysis of 6 national survey series. Alcohol Clin Exp Res 42(10):1939\u20131950. https:\/\/doi.org\/10.1111\/acer.13859","journal-title":"Alcohol Clin Exp Res"},{"key":"7087_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2017.03.016","volume":"177","author":"CL Haass-Koffler","year":"2017","unstructured":"Haass-Koffler CL, Goodyear K, Zywiak WH, Magill M, Eltinge SE, Wallace PM, Long VM, Jayaram-Lindstr\u00f6m N, Swift RM, Kenna GA, Leggio L (2017) Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin. Drug Alcohol Depend 177:23\u201328. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.03.016","journal-title":"Drug Alcohol Depend"},{"key":"7087_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci172889","author":"M Heilig","year":"2024","unstructured":"Heilig M, Witkiewitz K, Ray LA, Leggio L (2024) Novel medications for problematic alcohol use. J Clin Invest. https:\/\/doi.org\/10.1172\/jci172889","journal-title":"J Clin Invest"},{"issue":"17","key":"7087_CR22","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1007\/s00213-014-3590-6","volume":"231","author":"CM Helms","year":"2014","unstructured":"Helms CM, Park B, Grant KA (2014) Adrenal steroid hormones and ethanol self-administration in male rhesus macaques. Psychopharmacology 231(17):3425\u20133436. https:\/\/doi.org\/10.1007\/s00213-014-3590-6","journal-title":"Psychopharmacology"},{"issue":"8","key":"7087_CR23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM (2016) Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol 183(8):758\u2013764. https:\/\/doi.org\/10.1093\/aje\/kwv254","journal-title":"Am J Epidemiol"},{"issue":"24","key":"7087_CR24","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hern\u00e1n","year":"2022","unstructured":"Hern\u00e1n MA, Wang W, Leaf DE (2022) Target trial emulation: a framework for causal inference from observational data. JAMA 328(24):2446\u20132447. https:\/\/doi.org\/10.1001\/jama.2022.21383","journal-title":"JAMA"},{"key":"7087_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2015.00260","volume":"9","author":"VA Jimenez","year":"2015","unstructured":"Jimenez VA, Helms CM, Cornea A, Meshul CK, Grant KA (2015) An ultrastructural analysis of the effects of ethanol self-administration on the hypothalamic paraventricular nucleus in rhesus macaques. Front Cell Neurosci 9:260. https:\/\/doi.org\/10.3389\/fncel.2015.00260","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"7087_CR28","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/adb.12275","volume":"21","author":"GA Kenna","year":"2016","unstructured":"Kenna GA, Haass-Koffler CL, Zywiak WH, Edwards SM, Brickley MB, Swift RM, Leggio L (2016) Role of the \u03b11 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. Addict Biol 21(4):904\u2013914. https:\/\/doi.org\/10.1111\/adb.12275","journal-title":"Addict Biol"},{"key":"7087_CR29","doi-asserted-by":"publisher","unstructured":"de Kloet ER, Otte C, Kumsta R, Kok L, Hillegers MH, Hasselmann H, Kliegel D, Jo\u00ebls M (2016) Stress and Depression: a Crucial Role of the Mineralocorticoid Receptor. J Neuroendocrinol. 28(8). https:\/\/doi.org\/10.1111\/jne.12379","DOI":"10.1111\/jne.12379"},{"issue":"7","key":"7087_CR30","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ndt\/gfae004","volume":"39","author":"M Kobayashi","year":"2024","unstructured":"Kobayashi M, Girerd N, Zannad F (2024) When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases. Nephrol Dial Transplant 39(7):1063\u20131072. https:\/\/doi.org\/10.1093\/ndt\/gfae004","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1(Suppl 1","key":"7087_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neuropharm.2008.07.043","volume":"56","author":"GF Koob","year":"2009","unstructured":"Koob GF (2009) Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 56(Suppl 1(Suppl 1)):18\u201331. https:\/\/doi.org\/10.1016\/j.neuropharm.2008.07.043","journal-title":"Neuropharmacology"},{"issue":"5335","key":"7087_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1126\/science.278.5335.52","volume":"278","author":"GF Koob","year":"1997","unstructured":"Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278(5335):52\u201358. https:\/\/doi.org\/10.1126\/science.278.5335.52","journal-title":"Science"},{"key":"7087_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2023_424","author":"GF Koob","year":"2023","unstructured":"Koob GF, Vendruscolo L (2023) Theoretical Frameworks and Mechanistic Aspects of Alcohol Addiction: Alcohol Addiction as a Reward Deficit\/Stress Surfeit Disorder. Curr Top Behav Neurosci. https:\/\/doi.org\/10.1007\/7854_2023_424","journal-title":"Curr Top Behav Neurosci"},{"issue":"5","key":"7087_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.alcohol.2008.03.128","volume":"42","author":"L Leggio","year":"2008","unstructured":"Leggio L, Ferrulli A, Cardone S, Miceli A, Kenna GA, Gasbarrini G, Swift RM, Addolorato G (2008) Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcohol-dependent patients: a longitudinal study. Alcohol 42(5):375\u2013381. https:\/\/doi.org\/10.1016\/j.alcohol.2008.03.128","journal-title":"Alcohol"},{"issue":"13","key":"7087_CR35","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1021\/acschemneuro.2c00326","volume":"13","author":"AH L\u00e9k\u00f3","year":"2022","unstructured":"L\u00e9k\u00f3 AH, McGinn MA, Farokhnia M (2022) The mineralocorticoid receptor: an emerging pharmacotherapeutic target for alcohol use disorder? ACS Chem Neurosci 13(13):1832\u20131834. https:\/\/doi.org\/10.1021\/acschemneuro.2c00326","journal-title":"ACS Chem Neurosci"},{"key":"7087_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/joim.70021","author":"A Loften","year":"2025","unstructured":"Loften A, Farokhnia M, Vendruscolo LF, Leggio L (2025) Neuroendocrinology meets addiction: emerging pharmacotherapies on the horizon. J Intern Med. https:\/\/doi.org\/10.1111\/joim.70021","journal-title":"J Intern Med"},{"key":"7087_CR37","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae088","author":"XJ Maddern","year":"2024","unstructured":"Maddern XJ, Ursich LT, Bailey G, Pearl A, Anversa RG, Lawrence AJ, Walker LC (2024) Sex differences in alcohol use: Is it all about hormones? Endocrinology. https:\/\/doi.org\/10.1210\/endocr\/bqae088","journal-title":"Endocrinology"},{"key":"7087_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.pbb.2018.07.011","volume":"175","author":"VH Makhijani","year":"2018","unstructured":"Makhijani VH, Van Voorhies K, Besheer J (2018) The mineralocorticoid receptor antagonist spironolactone reduces alcohol self-administration in female and male rats. Pharmacol Biochem Behav 175:10\u201318. https:\/\/doi.org\/10.1016\/j.pbb.2018.07.011","journal-title":"Pharmacol Biochem Behav"},{"key":"7087_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108337","volume":"181","author":"VH Makhijani","year":"2020","unstructured":"Makhijani VH, Irukulapati P, Van Voorhies K, Fortino B, Besheer J (2020) Central amygdala mineralocorticoid receptors modulate alcohol self-administration. Neuropharmacology 181:108337. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108337","journal-title":"Neuropharmacology"},{"issue":"17","key":"7087_CR40","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","volume":"330","author":"M McPheeters","year":"2023","unstructured":"McPheeters M, O\u2019Connor EA, Riley S, Kennedy SM, Voisin C, Kuznacic K, Coffey CP, Edlund MD, Bobashev G, Jonas DE (2023) Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis. JAMA 330(17):1653\u20131665. https:\/\/doi.org\/10.1001\/jama.2023.19761","journal-title":"JAMA"},{"issue":"7","key":"7087_CR41","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1111\/acer.14378","volume":"44","author":"V Milivojevic","year":"2020","unstructured":"Milivojevic V, Angarita GA, Hermes G, Sinha R, Fox HC (2020) Effects of Prazosin on provoked alcohol craving and autonomic and neuroendocrine response to stress in alcohol use disorder. Alcohol Clin Exp Res 44(7):1488\u20131496. https:\/\/doi.org\/10.1111\/acer.14378","journal-title":"Alcohol Clin Exp Res"},{"key":"7087_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2017.06.014","volume":"43","author":"A Mirijello","year":"2017","unstructured":"Mirijello A, Tarli C, Vassallo GA, Sestito L, Antonelli M, d\u2019Angelo C, Ferrulli A, De Cosmo S, Gasbarrini A, Addolorato G (2017) Alcoholic cardiomyopathy: what is known and what is not known. Eur J Intern Med 43:1\u20135. https:\/\/doi.org\/10.1016\/j.ejim.2017.06.014","journal-title":"Eur J Intern Med"},{"key":"7087_CR43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejim.2022.04.005","volume":"101","author":"A Mirijello","year":"2022","unstructured":"Mirijello A, Sestito L, Lauria C, Tarli C, Vassallo GA, Antonelli M, d\u2019Angelo C, Ferrulli A, Crea F, Cossari A, Leggio L, De Cosmo S, Gasbarrini A, Addolorato G (2022) Echocardiographic markers of early alcoholic cardiomyopathy: six-month longitudinal study in heavy drinking patients. Eur J Intern Med 101:76\u201385. https:\/\/doi.org\/10.1016\/j.ejim.2022.04.005","journal-title":"Eur J Intern Med"},{"issue":"7","key":"7087_CR44","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.biopsych.2009.04.016","volume":"66","author":"R Mitra","year":"2009","unstructured":"Mitra R, Ferguson D, Sapolsky RM (2009) Mineralocorticoid receptor overexpression in basolateral amygdala reduces corticosterone secretion and anxiety. Biol Psychiatry 66(7):686\u2013690. https:\/\/doi.org\/10.1016\/j.biopsych.2009.04.016","journal-title":"Biol Psychiatry"},{"issue":"8","key":"7087_CR45","first-page":"1163","volume":"12","author":"AM Molinari","year":"2013","unstructured":"Molinari AM, Machado-Rada MY, Mazaira GI, Erlejman AG, Galigniana MD (2013) Molecular basis of mineralocorticoid receptor action in the nervous system. CNS Neurol Disord Drug Targets 12(8):1163\u20131174","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"2","key":"7087_CR46","doi-asserted-by":"publisher","first-page":"24","DOI":"10.71079\/aside.im.03222516","volume":"1","author":"M Nassar","year":"2025","unstructured":"Nassar M, Abosheaishaa H, Elfert K, Beran A, Ismail A, Mohamed M, Misra A, Essibayi MA, Altschul DJ, Azzam AY (2025) TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias considerations in clinical research. Aside Intern Med 1(2):24\u201333. https:\/\/doi.org\/10.71079\/aside.im.03222516","journal-title":"Aside Intern Med"},{"issue":"12","key":"7087_CR47","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1038\/s41386-021-01117-z","volume":"46","author":"VA Palzes","year":"2021","unstructured":"Palzes VA, Farokhnia M, Kline-Simon AH, Elson J, Sterling S, Leggio L, Weisner C, Chi FW (2021) Effectiveness of spironolactone dispensation in reducing weekly alcohol use: a retrospective high-dimensional propensity score-matched cohort study. Neuropsychopharmacology 46(12):2140\u20132147. https:\/\/doi.org\/10.1038\/s41386-021-01117-z","journal-title":"Neuropsychopharmacology"},{"key":"7087_CR48","unstructured":"Patibandla S, Heaton J, Kyaw H (2023) Spironolactone. StatPearls Publishing, Treasure Island (FL). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554421\/"},{"key":"7087_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2019.100149","volume":"10","author":"MR Peltier","year":"2019","unstructured":"Peltier MR, Verplaetse TL, Mineur YS, Petrakis IL, Cosgrove KP, Picciotto MR, McKee SA (2019) Sex differences in stress-related alcohol use. Neurobiol Stress 10:100149. https:\/\/doi.org\/10.1016\/j.ynstr.2019.100149","journal-title":"Neurobiol Stress"},{"key":"7087_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105427","volume":"154","author":"CL Pince","year":"2023","unstructured":"Pince CL, Whiting KE, Wang T, L\u00e9k\u00f3 AH, Farinelli LA, Cooper D, Farokhnia M, Vendruscolo LF, Leggio L (2023) Role of aldosterone and mineralocorticoid receptor (MR) in addiction: a scoping review. Neurosci Biobehav Rev 154:105427. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105427","journal-title":"Neurosci Biobehav Rev"},{"issue":"10","key":"7087_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-019-0984-1","volume":"21","author":"IB Puddey","year":"2019","unstructured":"Puddey IB, Mori TA, Barden AE, Beilin LJ (2019) Alcohol and hypertension-new insights and lingering controversies. Curr Hypertens Rep 21(10):79. https:\/\/doi.org\/10.1007\/s11906-019-0984-1","journal-title":"Curr Hypertens Rep"},{"issue":"2","key":"7087_CR52","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/acer.14989","volume":"47","author":"MA Raskind","year":"2023","unstructured":"Raskind MA, Williams T, Holmes H, Hart K, Crews L, Poupore EL, Thomas RG, Darnell J, Daniels C, Goke K, Hendrickson R, Terry G, Mayer C, Simpson T, Saxon A, Rasmussen D, Peskind ER (2023) A randomized controlled clinical trial of prazosin for alcohol use disorder in active duty soldiers: predictive effects of elevated cardiovascular parameters. Alcohol Clin Exp Res 47(2):348\u2013360. https:\/\/doi.org\/10.1111\/acer.14989","journal-title":"Alcohol Clin Exp Res"},{"issue":"6","key":"7087_CR53","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/acer.12441","volume":"38","author":"DD Rasmussen","year":"2014","unstructured":"Rasmussen DD, Beckwith LE, Kincaid CL, Froehlich JC (2014) Combining the \u03b11 -adrenergic receptor antagonist, prazosin, with the \u03b2-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone. Alcohol Clin Exp Res 38(6):1532\u20131539. https:\/\/doi.org\/10.1111\/acer.12441","journal-title":"Alcohol Clin Exp Res"},{"key":"7087_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines7040099","author":"J Rehm","year":"2019","unstructured":"Rehm J, Shield KD (2019) Global burden of alcohol use disorders and alcohol liver disease. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines7040099","journal-title":"Biomedicines"},{"issue":"3","key":"7087_CR55","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41380-024-02713-3","volume":"30","author":"RS Richardson","year":"2025","unstructured":"Richardson RS, Kryszak LA, Vendruscolo JCM, Koob GF, Vendruscolo LF, Leggio L (2025) GHSR blockade, but not reduction of peripherally circulating ghrelin via \u03b2(1)-adrenergic receptor antagonism, decreases binge-like alcohol drinking in mice. Mol Psychiatry 30(3):1047\u20131056. https:\/\/doi.org\/10.1038\/s41380-024-02713-3","journal-title":"Mol Psychiatry"},{"issue":"16","key":"7087_CR56","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1001\/jama.2023.4855","volume":"329","author":"RC Sheldrick","year":"2023","unstructured":"Sheldrick RC (2023) Randomized trials vs real-world evidence: how can both inform decision-making? JAMA 329(16):1352\u20131353. https:\/\/doi.org\/10.1001\/jama.2023.4855","journal-title":"JAMA"},{"issue":"2","key":"7087_CR57","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1530-0277.2008.00807.x","volume":"33","author":"TL Simpson","year":"2009","unstructured":"Simpson TL, Saxon AJ, Meredith CW, Malte CA, McBride B, Ferguson LC, Gross CA, Hart KL, Raskind M (2009) A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res 33(2):255\u2013263. https:\/\/doi.org\/10.1111\/j.1530-0277.2008.00807.x","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"7087_CR58","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/acer.12703","volume":"39","author":"TL Simpson","year":"2015","unstructured":"Simpson TL, Malte CA, Dietel B, Tell D, Pocock I, Lyons R, Varon D, Raskind M, Saxon AJ (2015) A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res 39(5):808\u2013817. https:\/\/doi.org\/10.1111\/acer.12703","journal-title":"Alcohol Clin Exp Res"},{"issue":"12","key":"7087_CR59","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1176\/appi.ajp.2018.17080913","volume":"175","author":"TL Simpson","year":"2018","unstructured":"Simpson TL, Saxon AJ, Stappenbeck C, Malte CA, Lyons R, Tell D, Millard SP, Raskind M (2018) Double-blind randomized clinical trial of prazosin for alcohol use disorder. Am J Psychiatry 175(12):1216\u20131224. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17080913","journal-title":"Am J Psychiatry"},{"issue":"5","key":"7087_CR60","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1176\/appi.ajp.2020.20050609","volume":"178","author":"R Sinha","year":"2021","unstructured":"Sinha R, Wemm S, Fogelman N, Milivojevic V, Morgan PM, Angarita GA, Hermes G, Fox HC (2021) Moderation of prazosin\u2019s efficacy by alcohol withdrawal symptoms. Am J Psychiatry 178(5):447\u2013458. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20050609","journal-title":"Am J Psychiatry"},{"key":"7087_CR61","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.alcohol.2021.08.004","volume":"96","author":"K Tezcan","year":"2021","unstructured":"Tezcan K, Yananli HR, Demirkapu MJ, G\u00f6ren MZ, Sakalli HE, Colombo G, G\u00fclhan R (2021) The effect of telmisartan, an angiotensin receptor blocker, on alcohol consumption and alcohol-induced dopamine release in the nucleus accumbens. Alcohol 96:73\u201381. https:\/\/doi.org\/10.1016\/j.alcohol.2021.08.004","journal-title":"Alcohol"},{"key":"7087_CR62","unstructured":"TriNetX (n.d.) TriNetX - The World\u2019s Largest, living ecosystem of Real-World Data and Evidence. Retrieved October 2 from https:\/\/www.trinet.com\/real-world-data\/"},{"issue":"4","key":"7087_CR63","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/m16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P (2017) Sensitivity analysis in observational research: introducing the E-Value. Ann Intern Med 167(4):268\u2013274. https:\/\/doi.org\/10.7326\/m16-2607","journal-title":"Ann Intern Med"},{"issue":"16","key":"7087_CR64","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jama.2023.4221","volume":"329","author":"SV Wang","year":"2023","unstructured":"Wang SV, Schneeweiss S, Franklin JM, Desai RJ, Feldman W, Garry EM, Glynn RJ, Lin KJ, Paik J, Patorno E, Suissa S, D\u2019Andrea E, Jawaid D, Lee H, Pawar A, Sreedhara SK, Tesfaye H, Bessette LG, Zabotka L, D\u2019Andrea E, Lee SB, Gautam N, York C, Zakoul H, Concato J, Martin D, Paraoan D, Quinto K (2023) Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA 329(16):1376\u20131385. https:\/\/doi.org\/10.1001\/jama.2023.4221","journal-title":"JAMA"},{"issue":"7","key":"7087_CR65","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21305","volume":"7","author":"L Wang","year":"2024","unstructured":"Wang L, Xu R, Kaelber DC, Berger NA (2024a) Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open 7(7):e2421305. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.21305","journal-title":"JAMA Netw Open"},{"issue":"8","key":"7087_CR66","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","volume":"29","author":"W Wang","year":"2024","unstructured":"Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R (2024b) Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Mol Psychiatry 29(8):2587\u20132598. https:\/\/doi.org\/10.1038\/s41380-024-02498-5","journal-title":"Mol Psychiatry"},{"issue":"1","key":"7087_CR67","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","volume":"30","author":"W Wang","year":"2024","unstructured":"Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R (2024c) Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med 30(1):168\u2013176. https:\/\/doi.org\/10.1038\/s41591-023-02672-2","journal-title":"Nat Med"},{"issue":"8","key":"7087_CR68","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.7326\/m23-2718","volume":"177","author":"W Wang","year":"2024","unstructured":"Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R (2024d) Association of semaglutide with tobacco use disorder in patients with type 2 diabetes: target trial emulation using real-world data. Ann Intern Med 177(8):1016\u20131027. https:\/\/doi.org\/10.7326\/m23-2718","journal-title":"Ann Intern Med"},{"issue":"1","key":"7087_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48780-6","volume":"15","author":"W Wang","year":"2024","unstructured":"Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R (2024e) Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun 15(1):4548. https:\/\/doi.org\/10.1038\/s41467-024-48780-6","journal-title":"Nat Commun"},{"issue":"9","key":"7087_CR70","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35247","volume":"7","author":"W Wang","year":"2024","unstructured":"Wang W, Volkow ND, Wang Q, Berger NA, Davis PB, Kaelber DC, Xu R (2024f) Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder. JAMA Netw Open 7(9):e2435247. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.35247","journal-title":"JAMA Netw Open"},{"issue":"12","key":"7087_CR71","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","volume":"20","author":"W Wang","year":"2024","unstructured":"Wang W, Wang Q, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R (2024g) Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimers Dement 20(12):8661\u20138672. https:\/\/doi.org\/10.1002\/alz.14313","journal-title":"Alzheimers Dement"},{"issue":"3","key":"7087_CR72","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jnci\/djae260","volume":"117","author":"L Wang","year":"2025","unstructured":"Wang L, Wang Q, Li L, Kaelber DC, Xu R (2025) Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data. J Natl Cancer Inst 117(3):476\u2013485. https:\/\/doi.org\/10.1093\/jnci\/djae260","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"7087_CR73","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/adm.0000000000000413","volume":"12","author":"CE Wilcox","year":"2018","unstructured":"Wilcox CE, Tonigan JS, Bogenschutz MP, Clifford J, Bigelow R, Simpson T (2018) A randomized, placebo-controlled, clinical trial of prazosin for the treatment of alcohol use disorder. J Addict Med 12(5):339\u2013345. https:\/\/doi.org\/10.1097\/adm.0000000000000413","journal-title":"J Addict Med"},{"key":"7087_CR74","doi-asserted-by":"publisher","unstructured":"Wilkinson CS, Bruns Nt, Pince CL, McGinn MA, Farokhnia M, Leggio L, Vendruscolo LF (2026) Dissecting the role of mineralocorticoid receptors in binge-like alcohol drinking in mice: Finerenone as a potential pharmacotherapy. Psychopharmacology (Berl). https:\/\/doi.org\/10.1007\/s00213-026-07035-6","DOI":"10.1007\/s00213-026-07035-6"},{"key":"7087_CR75","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.psyneuen.2018.09.010","volume":"105","author":"K Wingenfeld","year":"2019","unstructured":"Wingenfeld K, Otte C (2019) Mineralocorticoid receptor function and cognition in health and disease. Psychoneuroendocrinology 105:25\u201335. https:\/\/doi.org\/10.1016\/j.psyneuen.2018.09.010","journal-title":"Psychoneuroendocrinology"},{"key":"7087_CR76","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.alcohol.2025.01.003","volume":"123","author":"K Witkiewitz","year":"2025","unstructured":"Witkiewitz K, Leggio L (2025) Sex and gender differences in alcohol use disorder: Quo Vadis? Alcohol 123:121\u2013125. https:\/\/doi.org\/10.1016\/j.alcohol.2025.01.003","journal-title":"Alcohol"},{"issue":"9","key":"7087_CR77","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax4043","volume":"5","author":"K Witkiewitz","year":"2019","unstructured":"Witkiewitz K, Litten RZ, Leggio L (2019) Advances in the science and treatment of alcohol use disorder. Sci Adv 5(9):eaax4043. https:\/\/doi.org\/10.1126\/sciadv.aax4043","journal-title":"Sci Adv"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07087-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-026-07087-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07087-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:55:20Z","timestamp":1778756120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-026-07087-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":75,"alternative-id":["7087"],"URL":"https:\/\/doi.org\/10.1007\/s00213-026-07087-8","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Dr. Leggio reports, outside his federal employment at the NIH, honoraria from the UK Medical Council on Alcohol (Editor-in-Chief for Alcohol and Alcoholism) and book royalties from Routledge (as editor of a textbook). The other authors have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"Dr. Leggio reports, outside his federal employment at the NIH, honoraria from the UK Medical Council on Alcohol (Editor-in-Chief for Alcohol and Alcoholism) and book royalties from Routledge (as editor of a textbook). The other authors have nothing to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}